Srpski arhiv za celokupno lekarstvo 2012 Volume 140, Issue 1-2, Pages: 29-34
https://doi.org/10.2298/SARH1202029V
Full text ( 355 KB)
The effect of antiaggregational therapy on the long-term patency of the femoropopliteal/crural bypass
Vasić Dragan (Klinika za vaskularnu i endovaskularnu hirurgiju, Klinički centar Srbije, Beograd)
Radmili Oliver (Klinika za vaskularnu i endovaskularnu hirurgiju, Klinički centar Srbije, Beograd)
Davidović Lazar (Klinika za vaskularnu i endovaskularnu hirurgiju, Klinički centar Srbije, Beograd)
Vraneš Milica (Klinika za vaskularnu i endovaskularnu hirurgiju, Klinički centar Srbije, Beograd)
Introduction. Antiaggregational therapy can reduce thrombosis development
following the arterial reconstruction surgery. In most cases acetylsalicylic
acid and ticlopidine are used as antiaggregational agents. Objective. The aim
of this research was to examine the influence of different antiaggregational
agents on a long-term femoropopliteal/crural bypass patency. Methods. The
study involved 142 patients who underwent femoropopliteal/crural bypass
reconstructions at the Cardiovascular Disease Institute of the Clinical
Centre of Serbia. Most patient were operated on in the period from December
2007 to December 2009; however, the study also included a certain number of
patients who had undergone surgery 1-7 years earlier, and who were
postsurgically under a regular check-up and examination. Depending on the
administered antiaggregational agents, three groups of the patients were
formed: 1) patients on 100 mg/daily acetylsalicylic acid; 2) patients on
2Č250 mg/ daily ticlopidine; and 3) patients on 100 mg/daily acetylsalicylic
acid combined with 2Č250 mg/daily ticlopidine. Results. Among the formed
groups in our study, there was no statistically significant difference in the
femoropopliteal/crural bypass long-term patency, and the obtained patency
values for each group were in accordance to the data from the literature.
Conclusion. The first-choice antiaggregative agent after surgical
infrainguinal arterial reconstruction procedures was found to be
acetylsalicylic acid as compared to ticlopidin for at least two reasons: low
cost and absence of neuthropenia as a side-effect.
Keywords: femoropopliteal/crural bypass, antiaggregational therapy, long-term patency